![Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6513643/bin/nCD010747-CMP-004-01.jpg)
Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC
![Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6513643/bin/nCD010747-CMP-002-05.jpg)
Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC
Abstracts of papers to be presented at the 32nd annual scientific session of the American College of Cardiology New Orleans, Lou
![Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6513643/bin/nCD010747-CMP-004-05.jpg)
Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC
![Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6513643/bin/nCD010747-CMP-004-02.jpg)
Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC
![Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6513643/bin/nCD010747-AFig-FIG01.jpg)
Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC
![No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course | SpringerLink No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12902-018-0291-x/MediaObjects/12902_2018_291_Fig1_HTML.png)
No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course | SpringerLink
![PDF) No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course PDF) No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course](https://i1.rgstatic.net/publication/327432786_No_changes_in_levels_of_bone_formation_and_resorption_markers_following_a_broad-spectrum_antibiotic_course/links/5b8f3a87a6fdcc1ddd0fe08a/largepreview.png)